Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eMonarcHER: Abemaciclib plus adjuvant endocrine therapy in high-risk HR+, HER2+ early breast cancer
jRCT2041210026Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Abemaciclib plus endocrine therapy with Placebo plus endocrine therapy (2 arms). Primary endpoint: Invasive Disease-Free Survival. Started Jul 2021; status: completed.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2041210026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210026.